Get the Stockscreener App
98.47
1.17%
-1.30
Sarepta Therapeutics Inc stock is traded at $98.47, with a volume of 191.79K.
It is down -1.17% in the last 24 hours and down -9.92% over the past month.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
See More
Previous Close:
$99.77
Open:
$99.65
24h Volume:
191.79K
Relative Volume:
0.24
Market Cap:
$9.58B
Revenue:
$1.64B
Net Income/Loss:
$121.85M
P/E Ratio:
63.94
EPS:
1.54
Net Cash Flow:
$-480.40M
1W Performance:
-6.59%
1M Performance:
-9.92%
6M Performance:
-20.90%
1Y Performance:
-19.15%
1-Day Range:
$98.08
$100.00
1-Week Range:
$97.91
$104.85
52-Week Range:
$97.91
$173.25
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Name
Sarepta Therapeutics Inc
Sector
Industry
Phone
617-274-4000
Address
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
98.58 | 9.58B | 1.64B | 121.85M | -480.40M | 1.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.82 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.26 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
577.62 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.88 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.54 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Nov-27-24 | Reiterated | Needham | Buy |
| Nov-25-24 | Initiated | H.C. Wainwright | Sell |
| Nov-07-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jul-29-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-26-24 | Downgrade | Citigroup | Buy → Neutral |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| May-28-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-13-23 | Resumed | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-21-23 | Initiated | Wedbush | Outperform |
| Oct-31-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-31-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-23-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-04-23 | Initiated | Citigroup | Buy |
| Mar-01-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-22-22 | Reiterated | BTIG Research | Buy |
| Dec-16-22 | Upgrade | UBS | Neutral → Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-05-22 | Reiterated | Needham | Buy |
| Dec-09-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-21 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Jan-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-11-21 | Downgrade | UBS | Buy → Neutral |
| Jan-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Jan-08-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-31-20 | Initiated | Mizuho | Buy |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Aug-21-19 | Reiterated | Needham | Buy |
| Jul-09-19 | Reiterated | Morgan Stanley | Overweight |
| Jul-01-19 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-11-19 | Reiterated | Credit Suisse | Outperform |
| Oct-12-18 | Initiated | Bernstein | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-26-18 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-14-18 | Resumed | BofA/Merrill | Buy |
| Sep-06-18 | Initiated | Credit Suisse | Outperform |
| Aug-01-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-21-18 | Reiterated | Robert W. Baird | Outperform |
| Jun-20-18 | Reiterated | Needham | Buy |
| Jun-19-18 | Reiterated | H.C. Wainwright | Buy |
View All
Sarepta Therapeutics Inc Stock (SRPT) Latest News
Antisense Oligonucleotides Market reached US$ 2,985.97 - openPR
Sarepta Therapeutics’ SWOT analysis: gene therapy leader’s stock poised for growth - Investing.com India
US Bancorp DE Sells 2,803 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
Charles Schwab Investment Management Inc. Acquires 12,000 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Bought by Smartleaf Asset Management LLC - Defense World
Sarepta stock touches 52-week low at $99.46 amid market challenges - Investing.com Australia
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases - Benzinga
Sarepta stock touches 52-week low at $99.46 amid market challenges By Investing.com - Investing.com South Africa
Leigh Syndrome Treatment Market Poised for Substantial Growth - openPR
Scotiabank Initiates Coverage of Sarepta Therapeutics (LSE:0L35) with Sector Perform Recommendation - Nasdaq
Sarepta Therapeutics (NASDAQ:SRPT) Coverage Initiated at Scotiabank - Defense World
Scotiabank Initiates Coverage of Sarepta Therapeutics (SRPT) with Sector Perform Recommendation - Nasdaq
CLASS ACTION UPDATE for SRPT, MDP and CC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
Sarepta Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Scotiabank sets Sarepta stock target at $105, rates Sector Perform - Investing.com
Sarepta initiated with a Sector Perform at Scotiabank - TipRanks
Exploring 3 High Growth Tech Stocks In The US Market - Simply Wall St
Statutory Earnings May Not Be The Best Way To Understand Sarepta Therapeutics' (NASDAQ:SRPT) True Position - Yahoo Finance
Gene Therapy Market Global Forecast to 2032: Biopharma Giants Lead Gene Therapy Market Expansion – Latest Developments & Projections - Yahoo Finance
Interesting SRPT Put And Call Options For April 25th - Nasdaq
Global Cell and Gene Therapy Manufacturing Market to Reach ~USD 10 Billion by 2032 | DelveInsight - Yahoo Finance
Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Low P/S No Reason For Excitement - Simply Wall St
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.
Cantor Fitzgerald maintains Sarepta stock Overweight with $163 target - Investing.com
Sarepta Therapeutics' Long-Term Potential Intact Despite Near-Term Stock Weakness (SRPT) - Seeking Alpha
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4 - The Globe and Mail
Sarepta Therapeutics Inc Files For Mixed Shelf Size Not DisclosedSEC Filing -March 03, 2025 at 04:04 pm EST - Marketscreener.com
Sarepta Therapeutics (SRPT) Lags Q4 Earnings Estimates - MSN
Needham & Company LLC Reiterates Buy Rating for Sarepta Therapeutics (NASDAQ:SRPT) - Defense World
HC Wainwright Reaffirms “Sell” Rating for Sarepta Therapeutics (NASDAQ:SRPT) - Defense World
Sarepta Therapeutics (NASDAQ:SRPT) Sets New 1-Year Low on Analyst Downgrade - Defense World
Sarepta Therapeutics, Inc. SEC 10-K Report - TradingView
Sarepta Therapeutics (NASDAQ:SRPT) Reaches New 52-Week Low After Analyst Downgrade - MarketBeat
Royal Bank of Canada Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $161.00 - MarketBeat
Sarepta price target lowered to $210 from $217 at BofA - Yahoo Finance
Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program - Joplin Globe
Need College Funds? Sarepta Offers $5,000 Scholarships for Duchenne Patients and Siblings - StockTitan
Sarepta Therapeutics' (SRPT) Sell Rating Reaffirmed at HC Wainwright - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Investor Network: Sarepta Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Sarepta Q4 Earnings Lag Estimates, Revenues Gain on Gene Therapy Sales - MSN
Sarepta Therapeutics (SRPT) Projected to Post Earnings on Wednesday - MarketBeat
Sarepta Therapeutics’ Earnings Call Highlights Record Growth - TipRanks
Sarepta Stock Hits 52-Week Low at $101 Amid Challenges - Investing.com India
Sarepta Therapeutics (NASDAQ:SRPT) Releases Quarterly Earnings Results, Beats Estimates By $0.12 EPS - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Announces Earnings Results - MarketBeat
RBC Capital cuts Sarepta stock target to $161, maintains Outperform - Investing.com
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2024 Earnings Call Transcript - Insider Monkey
Optimistic Buy Rating for Sarepta Therapeutics Driven by Elevidys Potential and Expanding Pipeline - TipRanks
8 Analysts Have This To Say About Sarepta Therapeutics - Benzinga
Morgan Stanley Lifts Price Target on Sarepta Therapeutics to $196 From $195, Keeps Overweight Rating - Marketscreener.com
Sarepta Therapeutics Inc Stock (SRPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sarepta Therapeutics Inc Stock (SRPT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Estepan Ian Michael | Chief Financial Officer |
Jan 29 '25 |
Option Exercise |
12.00 |
15,800 |
189,600 |
49,496 |
| Wigzell Hans Lennart Rudolf | Director |
Dec 12 '24 |
Option Exercise |
13.71 |
10,500 |
143,955 |
33,340 |
| Wigzell Hans Lennart Rudolf | Director |
Dec 12 '24 |
Sale |
124.84 |
10,500 |
1,310,820 |
22,840 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):